Vivani Medical appoints Daniel Bradbury to Board; former Amylin CEO led first once-weekly GLP-1 drug

Vivani Medical, Inc.

Daniel Bradbury appointed to board effective March 4, 2024, filling newly created vacancy expanding board from 5 to 6 members.
Bradbury was CEO of Amylin Pharmaceuticals until its $7.1B acquisition by Bristol-Myers Squibb in 2012; Amylin secured first once-weekly GLP-1 approval (Bydureon).
He will serve on Audit Committee; annual retainers: $35,000 for board, $10,000 for committee.
His GLP-1 expertise aligns with Vivani's lead programs: six-month GLP-1 implants NPM-115 (obesity) and NPM-119 (type 2 diabetes).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel Bradbury

Director

VANI · Vivani Medical, Inc.

Effective: 2024-03-04
Filed: March 6, 2024, 6:59 PM ET

unanimously appointed Daniel Bradbury to fill a newly created vacancy on the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Bradbury was appointed as Director at Vivani Medical, Inc..

Action: appointed
Role: Director

Exact text from the filing

unanimously appointed Daniel Bradbury to fill a newly created vacancy on the Board

View on SEC.gov

Vivani Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001753926-24-000474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.